Jump to main content
Takeda will discontinue global manufacturing of NATPARA by the end of 2024. Learn How This May Affect You
NATPARA logo.

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA logo.

Managing
Hypoparathyroidism

Managing hypoparathyroidism requires careful monitoring2

In stable patients:

  • Serum calcium, phosphorous/phosphate, magnesium, BUN/creatinine and eGFR at least yearly
  • 24-hour urine collection for calcium and creatinine yearly

During dose adjustments:

  • More frequent monitoring, often several times per week, until a stable serum calcium concentration is achieved

For dosing and monitoring specific to NATPARA, click here.

Aim for low-normal, albumin-corrected total serum calcium levels2,3

For patients being treated for hypoparathyroidism, serum calcium levels are typically maintained at the lower end of the normal range (approximately 8.0 to 9.0 mg/dL).2

Albumin-corrected total serum
calcium levels1-4

Graph showing the target calcium range for people being targeted for hypoparathyroidism.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Brandi ML, Bilezikian JP, Shock D, et al. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi: 10.1210/jc.2015-3907. 3. Shoback D. N Engl J Med. 2008;359(4):391-403. 4. Fong J, Khan A. Can Fam Physician. 2012;58(2):158-162.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.

Takeda logo.

© 2023 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited.
US-NAT-0579v1.0 01/24

All content in this site, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda Pharmaceutical Company Limited makes reasonable efforts to include accurate, up-to-date information on this site, Takeda Pharmaceutical Company Limited makes no warranties or representations as to its accuracy. Takeda Pharmaceutical Company Limited assumes no liability for any errors or omissions in the content of this site.